Inter-alia, an implantable lens is disclosed comprising a refractive element causing chromatic aberration and an element inducing an increase of the chromatic aberration. It is further disclosed a method for producing an implantable lens.
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS (Germany)
UNIVERSITÄT HEIDELBERG (Germany)
Inventor
Bunse, Lukas
Chih, Yu-Chan
Green, Edward
Kilian, Michael
Krämer, Christopher
Platten, Michael
Wick, Wolfgang
Abstract
The present invention relates to a binding polypeptide comprising a first variable T cell receptor (TCR) domain and a second variable TCR domain wherein (i) the complementarity determining region 3 (CDR3) of the first variable TCR domain comprises, preferably consists of, the amino acid sequence of SEQ ID NO:1 or a sequence at least 80% identical thereto; and/or wherein the CDR3 of the second variable TCR domain comprises, preferably consists of, the amino acid sequence of SEQ ID NO:2 or a sequence at least 80% identical thereto; or wherein (ii) the CDR3 of the first variable TCR domain comprises, preferably consists of, the amino acid sequence of SEQ ID NO:3 or a sequence at least 80% identical thereto; and/or wherein the CDR3 of the second variable TCR domain comprises, preferably consists of, the amino acid sequence of SEQ ID NO:4 or a sequence at least 80% identical thereto; and to polynucleotides, host cells, methods, uses, kits, and devices related thereto.
The present invention relates to cyclic peptide compounds which inhibit or antagonize the binding of methylglyoxal (MG) and/or other reactive carbonyl species (RCS) to an arginine- or lysine- containing protein. Preferred scavenger compounds are said cyclic peptides comprising at least two lysines, at least one amino acid with an acidic side chain, at least one Dap and a hydrophobic modification, and pharmaceutical compositions thereof. The present invention furthermore relates to the use of the cyclic peptides as scavenger or antagonists of methylglyoxal and/or related reactive carbonyl species (RCS). The present invention furthermore relates to the use of the cyclic peptides for the prevention and/or treatment of a disease caused by or associated with methylglyoxal (MG) and/or reactive carbonyl species (RCS), in particular caused by or associated with elevated MG levels, such as diabetes and its associated complications, cardiovascular diseases and obesity.
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
C07K 7/56 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
C07K 7/64 - Cyclic peptides containing only normal peptide links
5.
COMPOSITION COMPRISING CYTIDINE ANALOGS AND USES AND METHODS THEREOF
The present invention provides a composition comprising a cytidine analog, in particular decitabine or azacitidine. In particular, the present invention provides a composition comprising a cytidine analog, in particular decitabine or azacitidine, which is useful for topical application. The present invention also provides the use of such compositions for medical conditions in the keratinizing and non-keratinizing epithelium/skin, such as the treatment of human papillomavirus (HPV)-related pre-cancerous conditions.
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS (Germany)
UNIVERSITÄT HEIDELBERG (Germany)
Inventor
Wardemann, Hedda
Murugan, Rajagopal
Bartenschlager, Ralf
Kim, Heeyoung
Abstract
The present invention concerns the field of therapeutic and diagnostic antibodies against SARS-CoV-2. Specifically, the invention relates to an antibody which specifically binds to the receptor binding domain (RBD) of SARS-CoV-2 spike protein with an equilibrium dissociation constant (Kd) of less than 10-9 M. The present invention further relates to a polynucleotide encoding the antibody of the invention, a vector or expression construct comprising said polynucleotide, a host cell comprising said polynucleotide, vector or expression construct, or a non-human transgenic organism comprising the polynucleotide, vector or expression construct of the invention. Yet, the invention relates to a method for producing the antibody of the invention and to the use of the host cell of the invention for producing the antibody of the invention. Moreover, the preset invention provides for using an antibody, a polynucleotide or a vector of the invention for treating and/or preventing a disease or condition or for using the antibody for diagnosing said disease or condition. Finally, the invention relates to a kit for diagnosing SARS-CoV-2 infection in a subject.
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS (Germany)
UNIVERSITÄT HEIDELBERG (Germany)
Inventor
Wardemann, Hedda
Murugan, Rajagopal
Bartenschlager, Ralf
Kim, Heeyoung
Abstract
The present invention relates to a method for identifying an antibody that binds the SARS-CoV-2 spike protein with high affinity, the method comprising the steps of: (a) determining the presence of IGKV1-39 in the light chain and/or IGHV3-9 in the heavy chain of said antibody; and (b) identifying an antibody that binds the SARS-CoV-2 spike protein with high affinity if IGKV1-39 is present in its light chain and/or IGHV3-9 is present in its heavy chain. The present invention also relates to a method for manufacturing an antibody, a method for assessing whether a subject produces antibodies that bind the SARS-CoV-2 spike protein with high affinity, and to uses, kits, antibodies, and polynucleotides related thereto.
The application relates to a sensor data processing module including a plurality of integrated circuit devices each configured to receive and process sensor data, in particular sensor data from a PET scanner, at least some of the integrated circuit devices each comprising: at least one data input for receiving measurement data from at least one sensor; at least one data input for receiving a plurality of sensor events from at least one other integrated circuit device, wherein each sensor event comprises at least a time information and an event information; and at least one data output for sending one or more sensor events; wherein the integrated circuit devices each comprise one or more FIFO buffers for temporarily storing one or more sensor events and the integrated circuit devices are each configured: to create one or more sensor events from the measurement data, wherein each sensor event comprises at least a time information and an event information; and to process the sensor events queued in the one or more FIFO buffers by sorting the sensor events located at the front of the queues at least based on the time information; and wherein at least two of the plurality of integrated circuit devices are connected such that the data output of one integrated circuit device is connected to the data input of at least one other integrated circuit device.
H04Q 9/00 - Arrangements in telecontrol or telemetry systems for selectively calling a substation from a main station, in which substation desired apparatus is selected for applying a control signal thereto or for obtaining measured values therefrom
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS (Germany)
UNIVERSITÄT HEIDELBERG (Germany)
Inventor
Martin-Villalba, Ana
Brügger, Britta
Vattulainen, Ilpo
Lolicato, Fabio
Gülcüler, Gülce Sila
Abstract
The present invention relates to an effector polypeptide comprising (i) an amino acid sequence at least 70% identical to the amino acid sequence RSNLGWLCLLLLPIPLIVWVKRK (SEQ ID NO: 1); and (ii) an exchange of an amino acid to a non-identical amino acid at least one position selected from the list consisting of positions 1, 2, 3, 19, 22, and 23 of the amino acid sequence of (i). The present invention also relates to a polynucleotide comprising a nucleic acid sequence encoding the aforesaid effector polypeptide, and to related host cells, pharmaceutical compositions, and uses, and to related uses in medicine, in particular in treating and/or preventing cancer, inflammatory disease, or acute or chronic neurodegenerative disease.
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS (Germany)
Inventor
Schmidt, Patrick
Zoernig, Inka
Jaeger, Dirk
Momburg, Frank
Berger, Aileen
Abstract
The present invention relates to an immunoreactive molecule that specifically recognises and binds to human Ankyrin Repeat Domain-Containing Protein 30A (NY- BR-1) and, in particular, to an immunoreactive molecule, which shows no cross- reactivity to other human Ankyrin repeat domain containing proteins. The invention further relates to the use of such immunoreactive molecules in the treatment of cancer as well as in companion diagnostics methods.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
in vitroin vitro methods for detecting Delta-like 1 (DLL1) protein using an anti-DLL1 capture antibody and a labeled anti-DLL1 detection antibody. According to the invention, these antibodies can be used in an in vitro method to diagnose a severe infection, in particular a sepsis.
The present invention relates to methods for assessing subjects presenting with suspected acute coronary syndrome. Specifically, the present invention relates to methods for classifying a patient with suspected acute coronary syndrome. The methods of the present invention may be carried out as computer-implemented methods.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
The present invention relates to a perivascular implant comprising (i) a housing comprising a receptacle for an effector matrix, and (ii) a fastening element adapted for at least partially embracing a tubular bodily structure, wherein said housing, said receptacle for an effector matrix, and said fastening element are arranged such that after implantation of the device the receptacle for an effector matrix at least partially is in contact with said tubular bodily structure and/or a vasculature originating from said tubular bodily structure, and to uses, methods, and kit related thereto.
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (Germany)
UNIVERSITAT HEIDELBERG (Germany)
Inventor
Sill, Martin
Pfister, Stefan
Jones, David
Von Deimling, Andreas
Capper, David
Hovestadt, Volker
Sahm, Felix
Schrimpf, Daniel
Abstract
The present disclosure pertains to an in vitro method for the diagnostic classification of cancer based on the biological state of specific genomic sites. The disclosure provides a method that allows for a classification of a tumour sample obtained from a patient by analysing a multitude, preferably genome wide, collection of gene sites, combining the biological state of the analysed gene sites into a biological state pattern and comparing with pre-determined biological state patterns pertaining to different cancer types or tumour species. The disclosure is in particular useful for classifying cancer e.g. of the central nervous system, such as brain tumour samples and tumours of the spinal cord, since these are characterized by a large variety of distinct tumour species which have different prognostic values and require a developed treatment regime for each species in the clinical context. However, other cancers could similarly profit from the disclosure, for example sarcomas.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G06F 9/50 - Allocation of resources, e.g. of the central processing unit [CPU]
G06F 15/78 - Architectures of general purpose stored program computers comprising a single central processing unit
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS (Germany)
UNIVERSITÄT HEIDELBERG (Germany)
Inventor
Sahm, Felix
Sill, Martin
Von Deimling, Andreas
Pfister, Stefan
Jones, David
Patel, Areeba
Dogan, Helin
Loose, Matt
Abstract
The present disclosure relates to a computer-implemented method for cancer diagnosis, comprising: a) selectively sequencing polymers of a biological sample according to at least one target gene site by translocating the polymers through nanopores of a nanopore sequencing system, including: (i) analyzing an initial nucleotide sequence of a first polymer of the biological sample while the first polymer is translocating through a nanopore of the nanopore sequencing system to determine whether the initial nucleotide sequence corresponds to the at least one target gene site; and (ii) continuing the sequencing of the first polymer to obtain measurement data of the first polymer only if the initial nucleotide sequence of the first polymer corresponds to the at least one target gene site; b) determining, based on the measurement data, a biological state of a nucleotide sequence of the first polymer corresponding to the at least one target gene site; and c) classifying a cancer using a classification algorithm based on the biological state of the nucleotide sequence of the first polymer, wherein the classification algorithm is trained based on the at least one target gene site and biological state data pertaining to cancer types.
The present invention relates to an endograft device (101) for treatment of ruptures (104.9) in one or more inner layers of a blood vessel (104), in particular, an aorta, comprising an anchoring unit (101.1) and a sleeve unit (101.2). The endograft device (101) defines an upstream endograft end (101.3) and a downstream endograft end (101.4), upstream and downstream being defined, in an implanted state of the endograft device (101), in relation to a general natural blood flow defining a blood flow direction within the blood vessel (104). The anchoring unit (101.1) is a collapsible unit located at the upstream endograft end (101.3), wherein the anchoring unit (101.1) is configured to anchor, in the implanted state, the endograft device (101) within the blood vessel (104) by engaging an inner surface of the blood vessel (104) with an expanded anchoring section (101.5). The sleeve unit (101.2) is located downstream of the anchoring unit (101.1), wherein the sleeve unit (101.2) is a thin- walled foldable element defining a longitudinal direction, a radial direction, a circumferential direction, an upstream sleeve unit end (101.7) and a upstream sleeve unit end (101.8). The sleeve unit (101.2) comprises an unsupported section (101.9) located at the upstream sleeve unit end (101.7), wherein the unsupported section (101.9) extends along the longitudinal direction and, at least in the implanted state, is unsupported over its entire circumference. The sleeve unit (101.2) is configured to be expanded, in the implanted state, to rest against an inner wall of the blood vessel (104) to sealingly cover the rupture (104.9) with the unsupported section (101.9).
A61F 2/848 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having means for fixation to the vessel wall, e.g. barbs
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS (Germany)
UNIVERSITÄT HEIDELBERG (Germany)
Inventor
Müller, Michael
Oehme, Ina
Witt, Olaf
Peterziel, Heike
Milde, Till
Abstract
The present invention relates to a method for identifying a subject susceptible to treatment of cancer by administration of a methylene quinuclidinone agent, said method comprising (a) determining in a sample of said subject at least four biomarkers independently selected from the group consisting of SLC7A11, PLS3, RHBDF1, CLDN1, FAM114A1, YAP1, TJP1, SEPTIN10; CORO1A, RHOH, CXCR4, PUM2, TRAF3IP3, KDM2B, ARHGAP9, IKZF1, ACAP1, and PDE7A; (b) comparing the result determined in step (a) to at least one reference, and (c), based on the result of step (b), identifying a subject susceptible to treatment of cancer by administration of a methylene quinuclidinone agent, and to compounds for use, kits, and devices related thereto.
The invention relates to a three-dimensional model for simulating medical, in particular dental, treatments, comprising at least one holding element for receiving artificial teeth and at least one artificial tooth, with the artificial tooth comprising at least one artificial tooth root and the artificial tooth root being at least partially held in a recess in the holding element. The object of providing a three-dimensional model with which realistic experience in the performance of both routine and complex dental and surgical interventions can be obtained inexpensively is achieved by a multiplicity of connecting strands being formed between the holding element and the artificial tooth, in particular the artificial tooth root. The invention also relates to a method for producing a three-dimensional model for simulating medical, in particular dental, treatments, in particular the three-dimensional model according to the invention, comprising at least one holding element for receiving artificial teeth and at least one artificial tooth, with the artificial tooth comprising at least one artificial tooth root and the artificial tooth root being at least partially held in a recess in the holding element, and also relates to a three-dimensional model for simulating medical, in particular dental, treatments, comprising at least one holding element, in particular for receiving artificial teeth, and an artificial nerve system comprising at least one artificial nerve, with the artificial nerve running at least partially through the holding means.
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
The present invention relates to xenon gas for use in vivo methods of sensitizing glioma cells in a subject for radiation therapy, as well as related in vitro methods.
The present invention relates to diagnosis and treatment of malignancies characterised by prostate-specific membrane antigen (PSMA) expression. The invention particularly relates to improved radiopharmaceuticals which selectively bind to PSMA and are suitable for planar imaging of PSMA expression in subjects to diagnose and/or monitor malignancies wherein PSMA is (over)expressed. Additionally, the invention relates to improved radiopharmaceuticals which selectively bind to PSMA and are suitable to act as radionuclide treatment agents. The radiopharmaceuticals rely on a pharmacophore capable of interacting with PSMA and N-terminal mercaptoacetyltripeptides capable of coordinating radioactive metals such as technetium and rhenium.
C07C 275/16 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
23.
INHIBITORS OF MITOFERRIN-2 FOR USE IN TREATING CANCER
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS (Germany)
UNIVERSITÄT HEIDELBERG (Germany)
Inventor
Tschaharganeh, Darjus
Krieg, Stephan
Abstract
The present invention relates to an inhibitor of mitoferrin-2 for use in treating a cancer with reduced activity of mitoferrin-1 in a subject. The present invention also relates to a method for identifying an inhibitor of mitoferrin-2 comprising (a) contacting a (i) host cell with a reduced mitoferrin-1 activity and (ii) a host cell with a non-reduced mitoferrin-1 activity with a candidate inhibitor of mitoferrin-2, (b) determining growth and/or morphology of the host cells of step (a); (c) identifying an inhibitor of mitoferrin-2 if a growth arrest and/or abnormal morphology is/are detected in step (b) in the host cell having the reduced activity of mitoferrin- 1 but not in the host cell with the non-reduced activity of mitoferrin-1. The present invention further relates to a method for identifying a subject susceptible to cancer treatment by an inhibitor of mitoferrin-2, comprising (A) determining mitoferrin-1 activity in a sample of said subject, preferably a sample of cancer cells, and (B) identifying a patient susceptible to cancer treatment by an inhibitor of mitoferrin-2 based on determining step (A).
The present disclosure provides variant AAV8 capsids that exhibit altered capsid properties, e.g., improved transduction efficiency and/or specificity for the liver. The present disclosure further provides nucleic acids encoding the variant AAV8 capsids, recombinant AAV (rAAV) vectors comprising the variant AAV8 capsids, as well as host cells and compositions comprising the same. The present disclosure further provides methods of delivering a gene product to a subject and methods of treatment of a liver-borne blood disorder, the methods generally involving administering an effective amount of the rAAV vectors to a subject in need thereof.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
e.g.e.g., enhanced immune-escaping capacity. Also provided are nucleic acids encoding the variant AAV8 capsid polypeptides, recombinant AAV (rAAV) vectors comprising the variant AAV8 capsid polypeptides, as well as host cells and pharmaceutical compositions comprising the same. Further provided are methods of delivering a gene product to a subject and methods of treatment of a liver-borne blood disorder, the methods generally involving administering an effective amount of the rAAV vectors to a subject in need thereof.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Summarizing the invention, a device is provided. The device comprises a sample tube comprising an open end; a cap configured to close the open end of the sample tube, the cap comprising a through-hole; a rod comprising a cavity, the rod being connected to the cap such that the cavity is in communication with the through-hole; and a swab tip connected to the rod such that the swab tip is in communication with the cavity; wherein the rod and the swab tip are configured to be positioned within the sample tube when the open end of the sample tube is closed by the cap.
A61B 10/00 - Other methods or instruments for diagnosis, e.g. for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
A61B 10/02 - Instruments for taking cell samples or for biopsy
The present invention relates to a polynucleotide encoding a nuclear polypeptide comprising a cargo polypeptide and an N-terminal activity-optimizing peptide (NAO peptide), wherein said NAO peptide comprises (i) a tag peptide, (ii) a linker peptide; and (iii) a nuclear localization sequence (NLS) peptide wherein said linker peptide comprises at least three small amino acids independently selected from glycine, alanine, leucine, serine, aspartate, asparagine, threonine, phenylalanine, glutamate, glutamine, histidine, arginine, lysine, valine, isoleucine, and proline, more preferably from glycine, alanine, proline, serine, valine, and threonine; and wherein said tag peptide is fused at its C-terminus to the linker peptide; and to vectors, polypeptides, host cells, and methods related thereto.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS (Germany)
UNIVERSITÄT HEIDELBERG (Germany)
Inventor
Tan, Chin Leng
Green, Edward
Platten, Michael
Lindner, Katharina
Bunse, Lukas
Sanghvi, Khwab
Abstract
The present invention relates to a method of identifying a T-cell reactive to cells presenting a T-cell activating antigen (cancer-reactive T-cell), comprising (a) determining expression of at least one of CCL4, CCL4L2, CCL3, CCL3L1, and CXCL13 in T-cells from a sample of a subject; and (b) identifying a cancer-reactive T-cell based on the determination of step (a). The present invention also relates to a method of identifying a TCR binding to a cancer cell of a subject, said method comprising (A) identifying a cancer reactive T-cell according to the afore-said method (B) providing the amino acid sequences of at least the complementarity determining regions (CDRs) of the TCR of the cancer-reactive T-cell identified in step (A); and, hereby, (C) identifying a TCR binding to a cancer cell. The present invention further relates to further methods and cancer-reactive T-cells related thereto.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS (Germany)
UNIVERSITÄT HEIDELBERG (Germany)
Inventor
Offringa, Rienk
Meng, Zibo
Rodriquez Ehrenfried, Aaron
Steffens, Laura Katharina
Tan, Chin Leng
Abstract
The present invention relates to a method of identifying a T-cell reactive to cells presenting a T-cell activating antigen (cancer-reactive T-cell), comprising (a) determining expression of at least one of CCL4, CCL4L2, CCL3, CCL3L1, and CXCL13 in T-cells from a sample of a subject; and (b) identifying a cancer-reactive T-cell based on the determination of step (a). The present invention also relates to a method of identifying a TCR binding to a cancer cell of a subject, said method comprising (A) identifying a cancer reactive T-cell according to the afore-said method (B) providing the amino acid sequences of at least the complementarity determining regions (CDRs) of the TCR of the cancer-reactive T-cell identified in step (A); and, hereby, (C) identifying a TCR binding to a cancer cell. The present invention further relates to further methods and cancer-reactive T-cells related thereto.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS (Germany)
UNIVERSITÄT HEIDELBERG (Germany)
UNIVERSITÄTSKLINIKUM MANNHEIM GMBH (Germany)
Inventor
Augustin, Hellmut G.
Grieshober, Denise
Hübers, Corinne
Pari, Ashik Ahmed Abdul
Felcht, Moritz
Abstract
The present invention relates to a method for predicting the risk of mortality of a subject suffering from cancer. The method comprises the steps of a) determining the amount of nANGPTL-4 (N-terminal fragment of angiopoietin like 4) in a first serum, plasma or blood sample from the subject, b) determining the amount of nANGPTL-4 (N-terminal fragment of an angiopoietin like 4) in a second serum, plasma or blood sample from the subject, wherein said second serum, plasma or blood sample has been obtained after said first sample, c) comparing the amount of nANGPTL-4 in the second blood, serum or plasma sample to the amount in the first blood, serum or plasma sample, and d) predicting the risk of mortality of the subject based on the results of step c).
The invention relates to a compound of general formula (I) in which X is selected from consisting of a first group, a second group or a third group, wherein the first group consists of and, the second group consists of and, and the third group consists of and; Y is a group of general formula II or of general formula (III) if X is selected from the first group, Z is selected from a first group consisting of if X is selected from the second group, Z is selected from a second group consisting of and; if X is selected from the third group, Z is selected from a third group consisting of and, R1and R21616 6 heteroalkyl group, -C(O)-O-Ra, -C(O)-NRbRc, -C(O)-C(Ra)2-NRbRc, and -C(O)-NRb22)n-C(O)- O-Ra, wherein Ra, Rband Rc166 heteroalkyl group, a substituted or unsubstituted aryl group and a group L and n is an integer from 1 to 10; R3is selected from the group consisting of oxygen, sulfur, =NRd, and =CHRd, wherein Rd16166 heteroalkyl group, a substituted or unsubstituted aryl group, -O-Re, -C(O)-O-Re, -C(O)-NRfRg166 alkyl group, and Rf and Rg166 alkyl group; and R4 is selected from the group consisting of -ORh, -SRh, -NHRh22Rh1616161622mm-NRmRn, a group -A-L and a group L, Rk16166 heteroalkyl group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted carboxy group, Rmand Rn166 alkyl group, and m is 0 or an integer from 1 to 10; R5and R6independently are selected from the group consisting of hydrogen, chloro, bromo, iodo, and O-Ro, wherein Ro166 alkyl group; A is a linker group and L is an amino acid residue or a peptide.
The present invention relates to a core-shell particle comprising a core cross-linked polymeric micelle (CCPM), and one or more iron oxide nanoparticles (IONs), wherein the one or more ION is located in the core of the CCPM. Further provided are methods for producing the core-shell particle, compositions comprising the same, the core-shell particle or the composition for use in medicine, and methods for modulating the activity of immune cells and methods of treating dysregulation of the immune system, cancer, anemia and nerve injuries.
The invention relates to oral pharmaceutical compositions of an active agent and a lipid conjugate of a cell penetrating peptide conjugated to a lipid molecule. The conjugated lipid acts as a permeation enhancer for the active agent in the composition. In other words, oral bioavailability of the active agent increases when co-administered together with the lipid conjugate described herein.
A61K 47/12 - Carboxylic acids; Salts or anhydrides thereof
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/18 - Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/42 - Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
The present invention relates to cobicistat and its derivatives or prodrugs for use in the prophylaxis and/or treatment of severe acute respiratory syndrome coronavirus type 2 (SARS- CoV-2) infection, severe acute respiratory syndrome coronavirus (SARS-CoV) infection and/or Middle East respiratory syndrome coronavirus (MERS-CoV) infection. The present invention further relates to methods of prevention and/or treatment of SARS-CoV-2 infection.
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
A61K 31/4418 - Non-condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
A61K 31/4433 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
A61K 31/4706 - 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
A61K 31/513 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
The present invention relates to a compound, a pharmaceutical composition comprising or consisting of said compound, a kit comprising or consisting of said compound or pharmaceutical composition and use of the compound or pharmaceutical composition for use in the in vivo diagnosis or treatment of ischemia.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
The present invention provides method of studying an effect of a test substance on a test sample of bio-logical cells using a set of relevant parameters and a set of meta-features, the method comprising: exposing the test sample to the test substance; determining parameter values of the set of relevant parameters for each of a plurality of cells in the test sample; and determining feature values of the set of meta-features for the test sample, wherein each of the feature values is calculated from the parameter values of a cluster of correlated parameters from the set of relevant parameters that is associated with the respective meta-feature, wherein a reference sample for determining the set of meta-features was exposed to a stimulus substance.
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) (France)
Inventor
Buj Bello, Ana
Renaud-Gabardos, Edith
Grimm, Dirk
Weinmann, Jonas
Abstract
The invention relates to the use of a recombinant porcine adeno-associated virus (AAV) vector comprising a peptide-modified porcine AAV serotype 1 (AAVpo1) capsid in gene therapy of muscle and/or central nervous system (CNS) disorders, in particular neuromuscular diseases such as genetic neuromuscular diseases.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
The present invention relates to a method for preparing a compound T having a thioether group from a compound D having a disulfide group in the presence of a carbene.
C07C 319/14 - Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
C07C 321/20 - Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
C07C 323/16 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
C07C 323/07 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and halogen atoms, or nitro or nitroso groups bound to the same carbon skeleton having sulfur atoms of thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
C07C 323/56 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
C07C 323/59 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
C07D 307/38 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
HOCHSCHULE KARLSRUHE - TECHNIK UND WIRTSCHAFT (Germany)
UNIVERSITÄT HEIDELBERG (Germany)
Inventor
Estana, Ramon
Gorenflo, Matthias
Ruhparwar, Arjang
Koehler, Felix
Poehler, Frank
Martens, Eckhard
Abstract
The disclosure in particular relates to a ventricular assist device for implantation into a lumen of a blood vessel, comprising an impeller fixed to a rotor shaft, wherein the impeller is configured to rotate around a longitudinal axis of the rotor shaft; a drive unit comprising a magnetic motor configured to cause rotation of the impeller around to the longitudinal axis; a first active magnetic bearing configured to bear a first end section of the rotor shaft relative to the drive unit; a second active magnetic bearing configured to bear a second end section of the rotor shaft relative to the drive unit; and a control unit configured to control the magnetic motor, the first active magnetic bearing and the second active magnetic bearing.
A61M 60/822 - Magnetic bearings specially adapted for being actively controlled
A61M 60/135 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable via, into, inside, in line, branching on, or around a blood vessel inside a blood vessel, e.g. using grafting
A61M 60/237 - Non-positive displacement blood pumps including a rotating member acting on the blood, e.g. impeller the blood flow through the rotating member having mainly axial components, e.g. axial flow pumps
A61M 60/422 - Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance - Details relating to driving for non-positive displacement blood pumps the force acting on the blood contacting member being electromagnetic, e.g. using canned motor pumps
A61M 60/861 - Connections or anchorings for connecting or anchoring pumps or pumping devices to parts of the patient’s body
40.
COMPOUNDS FOR TREATING PNEUMONIA, SEPSIS, AND CORONAVIRUS INFECTION
222-; Z is N or C, preferably is N; m is an integer of from 0 to 3, preferably is 0; n is an integer of from 1 to 3, preferably is 1; R156 6 cycloalkyl or aryl; R2is, optionally substituted, aryl or heteroaryl; R3and R4are -H, or R3and R4222- bridge; R5and R7are independently selected from alkyl, preferably methyl and isopropyl; and in case Z is N, R6is absent, or, in case Z is C, R6together with R5 forms a -CH=CH-CH=CH- bridge; and/or (ii) a C-C chemokine receptor type 5 (CCR5) inhibitor, for use in treating and/or preventing pneumonia, sepsis, and/or coronavirus infection in a subject, and to methods, uses, kits an devices related thereto.
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/431 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems containing further heterocyclic ring systems, e.g. ticarcillin, azlocillin, oxacillin
A61K 31/4706 - 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
C07C 233/02 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
C07C 233/02 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS (Germany)
Inventor
Nickel, Felix
Petersen, Jens
Onogur, Sinan
Schmidt, Mona
Kowalewski, Karl-Friedrich
Eisenmann, Matthias
Thiel, Christoph
Trent, Sarah
Weber, Christian
Abstract
The present disclosure provides a computer implemented method for facilitating a teaching surgeon to teach or assist a learning surgeon in minimally invasive interventions using a surgical instrument, said method comprising the following steps: displaying endoscopic images of an intervention site in real time on a display device, said endoscopic images being captured using a camera associated with an endoscopic instrument, tracking a movement of one or both hands of said teaching surgeon and/or a device held by said teaching surgeon, using a real-time tracking apparatus, wherein said real-time tracking apparatus comprises a tracking system and a computing device, wherein said tracking of said movement comprises the steps of recording a sequence of tracking information of one or both hands of said teaching surgeon and/or the device held by said teaching surgeon, said sequence of tracking information including real-time information regarding a movement of said one or both hands of the teaching surgeon and/or said device held by said teaching surgeon, and receiving, by said computing device or module, said recorded sequence of tracking information and extracting said real-time information regarding said movement of the one or both hands or the device from said recorded sequence of tracking information, and overlaying a visual representation of the tracked movement of said one or both hands or said device over the real-time endoscopic image, thereby allowing the teaching surgeon to carry out gestures with one or both hands which are displayed on the endoscopic image and allow for teaching or instructing the learning surgeon.
G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
G09B 9/00 - Simulators for teaching or training purposes
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS (Germany)
UNIVERSITÄT HEIDELBERG (Germany)
Inventor
Turchinovich, Andrey
Burwinkel, Barbara
Abstract
Summary The present invention relates to a method for the selective amplification or modification of DNA or RNA in a sample containing a mixture of RNA and DNA. Also, the present invention relates to the use of this method in detection, sequencing, DNA immunoprecipitation (DIP), methylation analysis, RNA immunoprecipitation (RIP), selective labelling of DNA or RNA molecules and massive parallel sequencing.
The present invention relates to artificial Antigen Presenting Cells (aAPCs) comprising artificial Antigen Presenting Molecules (aAPMs) and, in particular, comprising dimers of the aAPMs as well as to methods for producing aAPCs. The invention further relates to compositions comprising the aAPCs and to vectors encoding the aAPMs of the aAPCs. Embodiments of the invention have been particularly developed for use in assays for determining an antigen-specific T cell response or a plurality of antigen-specific T cell responses and will be described hereinafter with reference to this application. However, it will be appreciated that the invention is not limited to this particular field of use.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
46.
CONJUGATE COMPOUNDS FOR PREVENTING AND/OR TREATING HBV AND/OR HDV INFECTIONS, LIVER DISEASES AND FOR TARGETING NTCP
The present invention relates to conjugate compounds which comprise a peptide moiety (a) which is preferably a hydrophobic modified preS-derived peptide of hepatitis B virus or a respective cyclic peptide, and a NTCP substrate moiety (b), which is preferably a bile acid. The present invention further relates to pharmaceutical compositions comprising at least one conjugate compound. The present invention further relates to medical uses of said conjugate compounds and the pharmaceutical compositions, such as in the diagnosis, prevention and/or treatment of a liver disease or condition, and/or in the inhibition of HBV and/or HDV infection. The present invention further relates to methods of diagnosis, prevention and/or treatment of a said diseases and/or infections.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
22O is added into the autoclave as part of a solvent, and the pH value in the autoclave is set to a range above 7. The closed and filled autoclave is then heated for at least one hour and then cooled. The osteotropic bone replacement material produced in this manner is then cleaned of phosphorus, strontium, fluorine, and/or gallium source residue. The invention also relates to an osteotropic bone replacement material which substantially consists of apatite and in which strontium ions are incorporated into the crystalline lattice.
The present invention relates to an N-terminal fragment of an angiopoietin like 4 (ANGPTL4) polypeptide, or a therapeutically active variant thereof, for use in the treatment of cancer in a subject. Moreover, the present invention provides an agent which increases the amount of an N-terminal fragment of an angiopoietin like 4 (ANGPTL4) polypeptide for use in treating cancer. Further, encompassed by the present invention is a method for identifying a candidate compound for the treatment of cancer.
BERLINER INSTITUT FÜR GESUNDHEITSFORSCHUNG INSTITUTE OF HEALTH – BIH (Germany)
Inventor
Aschenbrenner, Sabine
Hoffmann, Mareike
Kallenberger, Stefan
Eils, Roland
Huck, Adrian
Niopek, Dominik
Abstract
The present invention relates to a method for modifying a target site in a host cell comprising contacting said host cell with a Cas nuclease, wherein said host cell is further contacted with a low-affinity Cas inhibitor and/or a sub-inhibitory concentration of a Cas inhibitor; and to a method for improving specificity of a Cas nuclease, comprising a) providing a Cas nuclease; and b) contacting said Cas nuclease with a low-affinity Cas inhibitor or a sub-inhibitory concentration of a Cas inhibitor; and c) thereby improving specificity of said Cas enzyme. Further, the present invention relates to compositions, polypeptides, uses and methods related thereto.
The present invention relates to compounds that inhibit expression of Id1 and/or Id3, as well as uses thereof in the treatment of cancer and other diseases and conditions associated with Id1 and/or Id3 expression.
C07D 209/12 - Radicals substituted by oxygen atoms
C07D 209/22 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
C07D 209/24 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
C07D 209/40 - Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
C07D 311/16 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
SCUOLA SUPERIORE DI STUDI UNIVERSITARI E DI PERFEZIONAMENTO SANT'ANNA (Italy)
UNIVERSITÄT HEIDELBERG (Germany)
Inventor
Masia, Lorenzo
Frisoli, Antonio
Tiseni, Luca
Chiaradia, Domenico
Xyloiannis, Michele
Solazzi, Massimiliano
Abstract
An underactuated mechanism (1), which allows the actuation of a distal degree of freedom of the shoulder joint and the transfer of the torques and the reaction force, generated by the actuation system on the frame (3) integral with the torso (5), through a hyper-redundant kinematic mechanism (200), is formed as follows: a. a first non -actuated rotoidal joint (100) connected to the human torso (5), which rotates about the axis X, b. a connection mechanism (200) connected to the first rotoidal joint (100), c. a second rotoidal joint (300) which (i) rotates about the axis Y arranged according to the degree of flexion-extension of the shoulder joint, which is coplanar with the axis X, (ii) is remotely actuated by a driven pulley and Bowden cables or by a direct drive actuation system with co-located motor, (iii) is fixed to the connection mechanism (200) on one side and to the human arm (6) on the other side, with the connection mechanism (200) consisting of: at least three or more members (210, 220, 231 ), two of which (210, 220) being rigidly fixed to one of the rotoidal joints (100, 300), respectively, all with parallel joints, referred to as minimum joints A and B, arranged so as to connect one member with the next one to form a rotation constraint about the axis of said parallel joints.
MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (Germany)
UNIVERSITÄT HEIDELBERG (Germany)
Inventor
Benk, Amelie S.
Benk, Lucia T.
Wegner, Seraphine
Comba, Peter
Spatz, Joachim P.
Abstract
The present invention relates to means and methods for conjugating/ attaching target molecules such as proteins to a label and/or carrier. Specifically, the present invention provides a complex comprising a metal cation coordinating (i) nitrate as a metal cation ligand and (ii) a metal cation chelating domain comprising a chelating ligand and a label and/or carrier. This complex can be used for attaching a label and/or a carrier to a target molecule, preferably a protein. The attachment of the label or carrier via the complex of the invention involves the replacement of the metal cation ligand with a coordinating group of the target molecule so that a product complex with the target molecule as primary ligand in the coordination sphere of the metal cation is formed. Accordingly, the present invention also provides for uses and methods involving the attachment of a label and/or carrier to a target molecule. Also provided are the products obtained by the labeling and or carrier-attaching methods of the invention and uses thereof. The invention further relates to methods for producing the complex of the invention and kits comprising the components for producing the complex of the invention.
A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (Germany)
UNIVERSITÄT HEIDELBERG (Germany)
Inventor
Benk, Amelie S.
Schenk, Franziska
Wegner, Seraphine
Comba, Peter
Spatz, Joachim P.
Abstract
33 2-33- and (ii) a metal cation chelating domain comprising a chelating ligand and a label and/or carrier. This complex can be used for attaching a label and/or a carrier to a target molecule, preferably a protein. The attachment of the label or carrier via the complex of the invention involves the replacement of the metal cation ligand with a coordinating group of the target molecule so that a product complex with the target molecule as primary ligand in the coordination sphere of the metal cation is formed. Accordingly, the present invention also provides for uses and methods involving the attachment of a label and/or carrier to a target molecule. Also provided are the products obtained by the labeling and or carrier-attaching methods of the invention and uses thereof. The invention further relates to methods for producing the complex of the invention and kits comprising the components for producing the complex of the invention.
A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
The present invention relates to a method for identifying a subject suffering from a severe form of a metabolic disease, comprising a) obtaining (i) at least partial nucleic acid sequences of at least two alleles of a gene contributing to said metabolic disease or at least partial amino acid sequences of the polypeptides expressed therefrom; and (ii) a residual activity of the polypeptides expressed from said at least two alleles, and b) based on the result of step a), identifying a subject suffering from a severe form of a metabolic disease; and to methods, data collections, devices, kit, and computer program products relates thereto.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/25 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups
55.
VLCFA-CONTAINING LIPIDS AS PROGNOSTIC AND PREDICTIVE MARKER FOR CANCER THERAPIES
The present invention relates to metabolic markers which are used as prognostic and/or predictive markers for a cancer therapy and/or for cancer therapy monitoring. The present invention further relates to methods for the prognosis and/or therapy monitoring of cancer, wherein said methods comprise determining the metabolome in a patient sample, in particular the amount of very long-chain fatty acid-containing lipids (VLCFA-containing lipids) in the metabolome.
The present invention relates to a method for diagnosing or prognosing cancer comprising determining in vitro cytosine methylation levels within marker genes and/or determining expression levels of miRNA markers.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
57.
COMPOUND DECREASING THE CONCENTRATION OF 2-HYDROXY-GLUTARATE
The present invention relates to a compound decreasing the concentration of 2-hydroxy- glutarate (2HG) in a subject for use in treating, preventing, and/or preventing progression of cardiac remodeling, in particular cardiomyopathy and/or heart failure and to viral particles, compositions, uses and methods related thereto.
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
58.
RELAXIN RECEPTOR 1 FOR USE IN TREATMENT AND PREVENTION OF HEART FAILURE
The present invention relates to a polynucleotide comprising an expressible nucleic acid sequence encoding a relaxin family peptide receptor (RXFP) polypeptide for use in treatment and/or prevention of heart failure in a subject. The present invention further relates to a vector comprising the polynucleotide of the present invention for use in treatment and/or prevention of heart failure, as well as to host cells, RXFP agonists, kits and devices related thereto.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
The present invention provides a method for analyzing an action of a stressor on a cell sample, the method comprising the following steps: a) exposing the cell sample to the stressor, b) acquiring a sample mass spectrometry profile of the cell sample, c) determining one or more values of one or more features of the sample mass spectrometry profile, and d) classifying the stressor using a model-based comparison of the one or more values of the features of the sample mass spectrometry profile with one or more reference stressors.
The present invention relates to a method of making an oral dosage form comprising the steps of reacting at least one cell penetrating peptide (CPP), purifying CPP-lipid conjugates, processing a lipid batch to obtain CPP-modified liposomes and incorporating a liposome lyophilisate into an oral dosage form. The present invention further relates to oral dosage forms and oral dosage forms for use in a therapeutic method.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
61.
LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PSMA-EXPRESSING CANCERS
The present invention relates to a compound of formula (1) (I), wherein Y3is O or S, wherein s, t, u and w are 0 or 1, wherein i is an integer of from 1 to 3, wherein j is an integer of from 3 to 5, and wherein Z1, Z2and Z322322, R 133 or H, X is selected from the group consisting of alkylaryl, aryl, alkylheteroaryl and heteroaryl, Y 1and Y 2are selected from the group consisting of aryl, alkylaryl, cycloalkyl, heterocycloalkyl, heteroaryl and alkylheteroaryl, and wherein A is a chelator residue having a structure selected from the group consisting of (la), (lb) and (lc), wherein R 2, R 3, R 4and R 52222 or wherein R 2and R 42nn- bridge with n being an integer of from 1 to 3, wherein n is preferably 2, and wherein r, v and q are 0 or 1, with the proviso that in case u and w are 0, q and v are 0, and (A) wherein u and w are 1, or (B) wherein u is 0 and w is 1, and wherein A is selected from (la) or (lb), or (C) wherein A is not The compound is disclosed for use in the treatment of PSMA- expressing cancer.
The present invention relates to antibiotics comprising at least one polypeptide of a length of 2 to 20 amino acids, wherein the N-terminus of the polypeptide is not attached to a lipophilic group and the polypeptide is positively charged.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Summary The present invention relates to compositions, methods, and devices for preventing irregular electromechanical waves in the myocardium that lead to pathological conditions as arrhythmia. In particular, the invention relates to compositions and methods to increase the conductivity of the myocardium to restore an impairment of the electrical conduction system of the heart. To that end substances with high conductivity, as carbon nanotube suspensions or metal nanowire suspensions, are injected in the myocardium at closely adjacent locations on circular or open lines or are introduced in patches of cardiomyocytes that are subsequently placed on the myocardium.
The present invention relates to a compound having a structure as shown in formula (I) or a pharmaceutically acceptable salt or prodrug thereof, wherein R1is ethyl, -H, or methyl and R2is a side chain having a structure as shown in formula (II) wherein X12222, X2to X4222, or R222, for use in treating and/or preventing of atrial arrhythmia in a subject. The present invention further relates to pharmaceutical compositions and kit related to said compound.
A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
The present invention relates to a polypeptide and a nucleic acid encoding the polypeptide for use in a method of detecting the presence of hepatitis D virus (HDV) and/or of diagnosing an HDV infection and/or of monitoring the treatment of an HDV infection. The present invention further relates to an in vitro method, an immunographic test device as well as a kit. In particular, the present invention relates to a point of care diagnostic for HDV infections.
The present invention relates to an adeno-associated virus (AAV) capsid polypeptide bonded to a binding peptide comprising an amino acid sequence RGDX1X2X3X4, with X1to X4 being independently selected amino acids, for use in treating and/or preventing a muscular disease and/or in muscle regeneration. The present invention further relates to polynucleotides, host cells, adeno-associated virus (AAV) capsids, pharmaceutical compositions, uses, and methods related to said AAV capsid polypeptide.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C07K 14/015 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
The present invention pertains to a method for producing a protein oligomer comprising at least two, and preferably three heterodimeric human NC-I-Fc proteins, the method comprising: a) culturing a host cell expressing (i) a fusion protein comprising, from N- to C-terminus, human NC-1 from collagen 18 fused to human IgGI Fc with "knob" mutations, or human IgGI Fc with "knob" mutations fused to human NC-1 from collagen 18, and (ii) human IgGI Fc with "hole" mutations, under conditions which allow the formation of a protein oligomer comprising at least two, and preferably three heterodimeric human NC-1-Fc proteins, and wherein the fusion protein of (i) and the human IgGI Fc with "hole" mutations of (ii) are expressed in a ratio of 2:1 or higher, and b) obtaining the protein oligomer comprising at least two, and preferably three heterodimeric human NC-1-Fc proteins.
A computer-implemented method for testing ocular drug delivery is provided. The ocular drug delivery is characterized by a set of delivery parameters comprising at least one of drug type, drug concentration, drug amount, injection position, penetration depth. The method comprises: providing a model for the human eye, wherein the model comprises: a geometry equation defining a three-dimensional generalized limacon for the geometry of the vitreous body, geometry equations describing all components of the eye; and a set of equations defining a drug convection in the vitreous body; setting a target drug state in the vitreous body; using the model to perform at least one simulation of the ocular drug delivery with a given set of values for the set of delivery parameters, wherein the at least one simulation provides a simulated drug state in the vitreous body; comparing the target drug state and the simulated drug state.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
70.
METABOLITE-BASED BREAST CANCER DETECTION AND DIAGNOSIS
The present invention relates to the use of a combination of metabolites contained in a sample of a mammalian subject in the in vitro or ex vivo early detection, diagnosis, prognosis and/or therapy monitoring of breast cancer. Said combination of metabolites comprises at least one amino acid selected from ornithine, threonine, tryptophane, glutamate, aspartate and histidine, at least one acylcarnitine and optionally further component(s). The present invention further relates to an in vitro or ex vivo method for the detection, diagnosis, prognosis and/or therapy monitoring of breast cancer, comprising providing a sample of a mammalian subject; determining the amount of a combination of metabolites; and comparing said amount with a control sample. The present invention further relates to a kit for performing said method.
The present invention relates to an expression construct encoding a short-hairpin activator protein-1 binding polynucleotide (shAP-1 binding polynucleotide), said shAP-1 binding polynucleotide comprising an activator protein 1 (AP-1) binding site sequence and a reverse complement of said AP-1 binding site sequence separated by a spacer sequence. Moreover, the present invention relates to a polyribonucleotide comprising an AP-1 binding site sequence and a reverse complement of said AP-1 binding site sequence separated by a spacer sequence, preferably produced or producible from the expression construct, and to viral particles, compositions, and uses related thereto.
The present invention relates to a method of predicting abnormal pregnancy outcome and a kit for carrying out the method. In particular, it relates to a method of predicting abnormal pregnancy outcome comprising measuring in a sample obtained from a patient, for example, a maternal blood or urine sample obtained early in the first trimester of gestation the amount of one or more markers and determining a ratio between said markers, wherein a change in the ratio is predictive for an abnormal pregnancy outcome.
The present invention relates to a compound, a liposome comprising said compound, a virus-like particle comprising said compound, a pharmaceutical composition comprising or consisting of said compound, said liposome or said virus-like particle, a kit comprising or consisting of said compound, said liposome, said virus-like particle or said pharmaceutical composition and use of the compound, liposome, virus-like particle or pharmaceutical composition in the treatment of a disease characterized by overexpression of fibroblast activation protein (FAP).
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C07H 15/252 - Naphthacene radicals, e.g. daunomycins, adriamycins
The present invention relates to a compound of formula (I), a pharmaceutical composition comprising or consisting of said compound, a kit comprising or consisting of said compound or pharmaceutical composition and use of the compound or pharmaceutical composition in the diagnosis or treatment of a disease characterized by overexpression of fibroblast activation protein (FAP).
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
URGO RECHERCHE INNOVATION ET DEVELOPPEMENT (France)
UNIVERSITÄT HEIDELBERG (Germany)
Inventor
Bouschbacher, Marielle
Steinbrunn, Julien Denis Marie
Lavigne, Louis
Gretz, Norbert
Becker, Anja
Hullen, Andreas
Klapczynski, Anna
Kuch, Natalia
Mu, Yifei
Abstract
A light source device (10) comprising a light emitting element (12) for emitting a light having the following characteristics: a wavelength ranging from 435 to 520 nm, and a power density greater than 20 mW/cm², the light source device (10) provides an effective fluence to any contaminating and/or pathogenic agent greater than 11 J/cm2. The invention is also directed to a light source assembly comprising a product adapted to be in contact with a support or a medium, preferably the skin or a wound and a light source device (10) connected to the product for providing light to at least one contaminating and/or pathogenic agent present on a support or in a medium (C).
The present invention relates to a compound, a device, in particular an organic light emitting diode or an electrofluorochrome device, which comprise the compound, and to the use of the compound as an electroluminescent material.
C07F 9/6564 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
H01L 51/50 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted for light emission, e.g. organic light emitting diodes (OLED) or polymer light emitting devices (PLED)
The invention relates to recombinant adeno-associated virus (rAAV) virions for gene therapy, wherein the rAAV virions comprise a novel capsid protein. In particular,the invention relates to the use of such virions in gene therapy for the treatment of an arthritic disease, such as for example rheumatoid arthritis, or symptoms thereof, preferably by intraarticular administration.
The present invention relates to a polynucleotide comprising a Nuclear factor of activated T-cells (NFAT) binding site sequence and a reverse complement of said NFAT binding site sequence separated by a spacer sequence, to said polynucleotide for use in treating and/or preventing disease, and to viral particles, compositions, and uses related thereto. The present invention further relates to a polynucleotide comprising a Nuclear factor of activated T-cells (NFAT) binding site sequence and a reverse complement of said NFAT binding site sequence for use in treating and/or preventing an NFAT-mediated disease.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
79.
A BODY FLUID LEAKAGE DETECTION AQUEOUS COMPOSITION
The present invention relates to the field of pharmacogenomics and in particular to detecting the presence of CpG methylation and mi RNAs in blood for the detection of cancer. This detection is useful for a minimally invasive diagnosis of cancer as well as for monitoring cancer treatment and assessing treatment response. The invention provides methods suitable for this purpose.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
81.
DELTA-LIKE LIGAND 1 FOR DIAGNOSING SEVERE INFECTIONS
The invention refers to a method for in vitro diagnosis of a severe infection comprising determining delta-like ligand 1 protein or a nucleotide sequence coding for delta-like ligand 1 protein in a biological sample wherein an elevated level of expression of delta- like ligand 1 protein or a nucleotide sequence coding for delta-like ligand 1 protein is indicative of a severe infection; and the use of delta-like ligand 1 protein as a biomarker for in vitro diagnosis of a severe infection such as sepsis.
The present invention relates to a polynucleotide encoding a fusion polypeptide comprising an anti-CRISPR (Acr) polypeptide, wherein said fusion polypeptide further comprises a receptor domain changing conformation upon reception of a stimulus. The present invention also relates to a vector comprising the polynucleotide of the present invention, to a bipartite Acr polypeptide comprising a first partial Acr polypeptide comprising amino acids corresponding to amino acids 10 to 62 of SEQ ID NO: 1, and a second partial Acr polypeptide comprising amino acids corresponding to amino acids 67 to 77 of SEQ ID NO: 1, and to a host cell comprising the aforesaid polynucleotide compounds. The present invention also relates to the said compounds for use in medicine, in particular for use in treatment and/or prevention of genetic disease, neurodegenerative disease, cancer, and/or infectious disease. Moreover, the present invention also relates to a kit, methods, and uses related thereto.
The present invention relates to a method for determining a survival probability of a subject suffering from colorectal cancer comprising a) detecting the methylation status of at least two CpG sites related to at least two CpG sites selected from cg16336556, cg14270346, cg05646575, cg17431888, cg12510999, cg00832644, cg11056055, cg08804626, cg14983135, cg22522598, cg19184885, cg08729279, cg10758824, cg18195165, cg08617020, cg23750514, cg01131395, cg18736676, cg19340296, and cg16399624 in a sample of said subject and, b) based on the methylation status detected in step a), determining the survival probability of said subject; and to a method for patient monitoring comprising the aforementioned steps and providing close monitoring and/or lifestyle recommendations in case an unfavorable survival probability and/or an increased mortality risk is detected. The present invention further relates to a data collection comprising the positions of at least two of the CpG sites of the invention and kits, devices, and uses related thereto.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
2P2P3.1 for use in the prevention and/or treatment of cardiac arrhythmia in a subject. The invention also relates to a nucleic acid molecule usable in the prevention and/or treatment of cardiac arrhythmia in a subject. The invention further relates to a cell comprising said nucleic acid molecule. The invention further relates to a vector comprising said nucleic acid molecule.
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
The present invention relates to a binding polypeptide specifically binding to an epitope comprised in an amino acid sequence corresponding to amino acids 250 to 300 of the norovirus genotype II.10 capsid polypeptide., and to a polynucleotide encoding the same. The present invention further relates to a composition comprising the binding polypeptide according to the present invention and a carrier, and to the binding polypeptide or the composition comprising the same use in diagnosis and/or for use in medicine. Further more, the present invention relates to kits, devices, vaccines, methods, and uses related to the binding polypeptide of the present invention.
The present invention relates to a polynucleotide comprising (i) a sequence encoding an anti- CRISPR (Acr) polypeptide and (ii) an miRNA target sequence and to vectors and host cells related thereto. The present invention further relates to a kit comprising (I) a first polynucleotide comprising (i) a sequence encoding an anti-CRISPR (Acr) polypeptide and (ii) an RNA-interference (RNAi) target sequence; and a Cas nuclease or a second polynucleotide comprising an expressible gene encoding a Cas nuclease; (II) a first polynucleotide comprising (i) a sequence encoding an anti-CRISPR (Acr) polypeptide and (ii) an RNA- interference (RNAi) target sequence, said first polynucleotide further comprising an expressible gene encoding a first fragment of a Cas nuclease, and a second polynucleotide comprising an expressible gene encoding a second fragment of a Cas nuclease, wherein said first and second fragment of said Cas nuclease together reconstitute an active Cas nuclease; or (III) a first polynucleotide comprising (i) a sequence encoding an anti-CRISPR (Acr) polypeptide, (ii) an RNA-interference (RNAi) target sequence, and (iii) a sequence encoding a Cas nuclease; and a second polynucleotide comprising an expressible gene encoding an inhibitory RNA, preferably a siRNA or a miRNA hybridizing to said RNAi target sequence, more preferably a siRNA hybridizing to said RNAi target sequence. Further, the present invention relates to methods and uses related to the aforesaid means.
The invention relates to a method for the diagnosis and/or risk stratification of invasive fungal infections (IFI) / invasive fungal diseases (IFD) and in particular associated with sepsis or septic shock, wherein a determination of the marker proadrenomedullin (proADM) or a partial peptide or fragment thereof, in particular midregional proadrenomedullin (MR-proADM), or contained in a marker combination (panel, cluster), is carried out from a patient to be examined. Furthermore, the invention relates to a diagnostic assay and a kit for carrying out the method.
The present invention relates to a phosphomimetic RAGE protein comprising an amino acid sequence that is at least 90 % identical to a native mammalian RAGE isoform or fragment thereof wherein at least one serine present in the cytoplasmatic tail of the mammalian RAGE isoform is replaced by a phosphomimetic structure. The invention further relates to a polynucleotide encoding phosphomimetic RAGE protein and a vector comprising the polynucleotide. Finally, the invention relates to a composition comprising carrier and an active pharmaceutical ingredient, selected from the RAGE protein the vector for use in the treatment or prevention of a disease in a patient, wherein the disease is preferably selected from a disease initiated by impaired DNA repair, a disease initiated by increased DNA damage or a disease initiated by increased senescence.
The present invention relates to methods for the physical sorting of cells, such as flow cytometry methods. In particular, the invention relates to methods in which the co-localization of at least two detectable markers is utilized to physically sort (and ultimately separate) cells. The present invention further relates to devices capable of performing said methods, to uses of the co-localization of the at least two detectable markers for the physical sorting of cells, to kits comprising at least two detectable markers and instructions for performing the methods, to uses of said kits, as well as to cells or cell pools that have been sorted, i.e. have been isolated or obtained, with such methods.
The present invention relates to compositions for the treatment of a malignant disease and in particular to compositions comprising an NF-κB inhibitor and a γ-glutamyltransferase (γ-GT) inhibitor and therapeutic uses thereof. The invention further relates to in vitromethods of testing putative anti-tumour agents for their potential to act as therapeutically effective anti- tumour agents in vivo. Embodiments of the invention have been particularly developed for bringing NF-κB inhibitors to the clinic such asto provide alternative therapeutic options in the treatment of malignant diseases and will be described hereinafter with reference to this application. However, it will be appreciated that the invention is not limited to this particular field of use.
The present invention relates to solid oral dosage forms comprising liposomes, said liposomes comprising conjugates of cell penetrating peptides (CPPs)and a compound, selected from a lipid and a fatty acid, wherein said liposomes are comprised in an enteric-coated capsule or enteric-coated tablet. The present invention further relates to uses of said solid oral dosage forms for the oral delivery of therapeutic and diagnostic agents.
The present invention relates to a method for producing (functionalized) biaryls by employing a visible-light-driven, gold-catalyzed C-C cross-coupling reaction system involving boron- and silicon-containing aryl compounds and aryldiazonium compounds. Moreover, the present invention relates to the use of such boron- and silicon-containing aryl compounds and aryldiazonium compounds, as well as related gold catalysts, in the manufacture of (functionalized) biaryls.
C07C 17/266 - Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions of hydrocarbons and halogenated hydrocarbons
C07C 67/343 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by change of size of the carbon skeleton by increase in the number of carbon atoms
C07C 41/30 - Preparation of ethers by reactions not forming ether-oxygen bonds by increasing the number of carbon atoms, e.g. by oligomerisation
C07C 315/04 - Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
C07C 45/68 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of C=O groups by change of size of the carbon skeleton by increase in the number of carbon atoms
C07C 253/30 - Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
THE EUROPEAN ATOMIC ENERGY COMMUNITY (EURATOM), REPRESENTED BY THE EUROPEAN COMMISSION (Belgium)
UNIVERSITÄT HEIDELBERG (Germany)
Inventor
Morgenstern, Alfred
Bruchertseifer, Frank
Apostolidis, Christos
Haberkorn, Uwe
Giesel, Frederik
Kratochwil, Clemens
Abstract
The invention relates to a method for treating PSMA expressing cancers, wherein the method comprises administering to patient in need thereof an effective amount of one or more Ac-225-radiopharmaceuticals, wherein the effective amount of said one or more Ac-225-radiopharmaceuticals is administered as a dosage of from 25kBq to 400kBq/kg of body weight of said patient or wherein the effective amount of said one or more Ac-225-radiopharmaceuticals is administered as a unitary dosage of from 3MBq to 30MBq to said patient.
The present invention relates to a method for analysing an object by means of nuclear magnetic resonance imaging. The method comprising - issuing a pulse sequence (1) to an NMR apparatus, the pulse sequence (1) comprising a plurality of acquisition phases (3); - within a respective acquisition phase (3), acquiring a corresponding set of imaging data; and - quantifying at least one contrast parameter of the object based on the acquired sets of imaging data and simulated data; wherein the acquisition phase (3) comprises the following steps in the given order: - an excitation step (5) for flipping a longitudinal magnetization of one or more nuclear spins in the object into a transversal plane by a variable flip-angle, thereby inducing a transversal magnetization; - an image readout step (6) for reading out the corresponding set of imaging data; and - a spoiling step (7) for depleting the transversal magnetization; wherein a timing of the steps and/or the flip-angle is varied between at least two of the plurality of acquisition phases (3). Further, the present invention relates to a corresponding computer program product, a control apparatus for NMR and to a nuclear magnetic resonance apparatus.
G01R 33/50 - NMR imaging systems based on the determination of relaxation times
G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
G01R 33/561 - Image enhancement or correction, e.g. subtraction or averaging techniques by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities
MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (Germany)
Inventor
Müllen, Klaus
Abdulkarim, Ali
Hinkel, Felix
Golling, Florian
Abstract
The present invention relates to a method for producing poly-(para-phenylene), to a poly-(para-phenyiene) compound obtained by said method, and to the use of said poly-(para-phenylene) compound in various applications. The poly-(para-phenylene) compound obtained by the method according to the present invention is unsubstituted, structurally defect-free as well as of sufficient chain length.
C08G 61/10 - Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aromatic carbon atoms, e.g. polyphenylenes
96.
SYNTHESIS AND STRUCTURE OF CHEMICALLY SWITCHABLE FLUORESCENT PROBES ON THE BASIS OF AMINO ACIDS
The present invention relates to a compound, comprising at least one chelate-forming group, at least one linker and at least one fluorophore, and to methods for increasing the resolution in the field of fluorescence microscopy for multiplexing in the field of fluorescence microscopy and for the quantitative detection of metal ions by the use of said compound.
G01N 33/542 - Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
A method and sensor array for identification of an analyte is disclosed. The method comprises preparing a plurality of solutions at a plurality of pH values of at least one fluorescent poly(para-phenyleneethynylene) and its complex(es), exposing the complex analyte to the plurality of the solutions and measuring the fluorescence intensity of the exposed complex analyte. The fluorescence intensity is compared with a library and the complex analyte identified from the comparison.
C08G 61/12 - Macromolecular compounds containing atoms other than carbon in the main chain of the macromolecule
G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
A magnetic resonance imaging-antenna (1; 2; 3; 4; 5; 6) comprises a first coil (10) comprising a first planar section (11) defining a first detection area (14), wherein the first planar section (11) is arranged within a first plane, and a second coil (20; 30) comprising a second planar section (21; 31) defining a second detection area (24; 34), wherein the second planar section (21; 31) is arranged within a second plane. Therein, the first coil (10) comprises a first bent section (12) that is bent out of the first plane of the first planar section (11).
The invention relates to a STED microscope and to a STED microscopy method. The STED microscope comprises: a light source for producing an excitation beam and a depletion beam; a first diffractive optical element (DOE1) and a second diffractive optical element (DOE2) each having a periodic arrangement of diffractive sub-elements, wherein the first diffractive optical element (DOE1) is designed to diffract an excitation beam in such a way that an array of punctiform excitation regions (20) is produced; and the second diffractive optical element (DOE2) is designed to diffract a depletion beam in such a way that an array of doughnut-shaped depletion regions (30) is produced.
The present invention relates to compounds that have the capability of inhibiting the secretion of fibroblast growth factor 2 (FGF2) by tumor cells, as well as uses of said compound in medicine, in particular in the prevention and/or treatment of cancerous or inflammatory diseases.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings